RESUMO

Resumen Objetivo: Describir la evolución de las cadenas livianas libres séricas (CLL) en el período comprendido entre el trasplante cardíaco ortotópico (TCO) y el trasplante de células progenitoras hematopoyéticas (TCPH), la respuesta hematológica al año tras el TCPH y el tratamiento quimioterápico e inmunosupresor en pacientes con amiloidosis AL. Método: Serie de casos de pacientes consecutivos con diagnóstico de amiloidosis AL que recibieron TCO seguido de TCPH del Registro Institucional de Amiloidosis del Hospital Italiano de Buenos Aires, entre enero de 2010 y noviembre de 2021. Se reportaron los valores de CLL entre trasplantes y al año del TCPH. Las variables cuantitativas se describieron como mediana e intervalo intercuartil, y las variables categóricas como frecuencias absolutas y relativas. Resultados: De 106 pacientes con amiloidosis AL, seis tuvieron TCO seguido de TCPH. La mediana de edad fue de 55 años. La mayoría eran hombres (n = 5). En el período entre trasplantes, la CLL involucrada disminuyó en dos pacientes y se mantuvo estable en tres. Todos lograron la remisión hematológica completa al año del TCPH. Un solo paciente presentó recaída en el órgano sólido trasplantado. Tacrolimus, micofenolato de mofetilo y corticoides fue el esquema inmunosupresor utilizado después del TCO. Conclusiones: El TCO representa una opción de tratamiento en pacientes con falla cardíaca grave por amiloidosis, permitiendo luego un tratamiento intensivo con quimioterapia de inducción y TCPH. Si bien faltan estudios, la terapia inmunosupresora después del TCO podría tener algún efecto sobre las células plasmáticas clonales.

Abstract Objective: To describe the evolution of serum free light chains (FLC) in the period between orthotopic heart transplantation (OHT) and autologous stem cell transplantation (ASCT), the hematological response one year after ASCT and chemotherapy and immunosuppressive treatment in patients with AL amyloidosis. Method: Case series of consecutive patients diagnosed with AL amyloidosis who received OHT followed by ASCT from the Institutional Registry of Amyloidosis of the Italian Hospital of Buenos Aires, between January 2010 and November 2021. FLC values between transplants and at year post ASCT. Quantitative variables were described with their median and interquartile range. Categorical variables as absolute and relative frequencies. Results: Of 106 patients with AL amyloidosis, 6 had an OHT followed by ASCT. The median age was 55 years. Most were men (n = 5). In the period between transplants, the involved CLL decreased in two patients and remained stable in three. All achieved complete hematologic remission 1 year after ASCT. A single patient presented relapse in the transplanted solid organ. Tacrolimus, mycophenolate mofetil, and corticosteroids were the immunosuppressive regimen used after OHT. Conclusions: OHT represents a treatment option in patients with severe heart failure due to amyloidosis, allowing later intensive treatment with induction chemotherapy and ASCT. Although studies are lacking, immunosuppressive therapy after OHT might have some effect on clonal plasma cells.

RESUMO

OBJECTIVE: To describe the evolution of serum free light chains (FLC) in the period between orthotopic heart transplantation (OHT) and autologous stem cell transplantation (ASCT), the hematological response one year after ASCT and chemotherapy and immunosuppressive treatment in patients with AL amyloidosis. METHOD: Case series of consecutive patients diagnosed with AL amyloidosis who received OHT followed by ASCT from the Institutional Registry of Amyloidosis of the Italian Hospital of Buenos Aires, between January 2010 and November 2021. FLC values between transplants and at year post ASCT. Quantitative variables were described with their median and interquartile range. Categorical variables as absolute and relative frequencies. RESULTS: Of 106 patients with AL amyloidosis, 6 had an OHT followed by ASCT. The median age was 55 years. Most were men (n = 5). In the period between transplants, the involved CLL decreased in two patients and remained stable in three. All achieved complete hematologic remission 1 year after ASCT. A single patient presented relapse in the transplanted solid organ. Tacrolimus, mycophenolate mofetil, and corticosteroids were the immunosuppressive regimen used after OHT. CONCLUSIONS: OHT represents a treatment option in patients with severe heart failure due to amyloidosis, allowing later intensive treatment with induction chemotherapy and ASCT. Although studies are lacking, immunosuppressive therapy after OHT might have some effect on clonal plasma cells.

OBJETIVO: Describir la evolución de las cadenas livianas libres séricas (CLL) en el período comprendido entre el trasplante cardíaco ortotópico (TCO) y el trasplante de células progenitoras hematopoyéticas (TCPH), la respuesta hematológica al año tras el TCPH y el tratamiento quimioterápico e inmunosupresor en pacientes con amiloidosis AL. MÉTODO: Serie de casos de pacientes consecutivos con diagnóstico de amiloidosis AL que recibieron TCO seguido de TCPH del Registro Institucional de Amiloidosis del Hospital Italiano de Buenos Aires, entre enero de 2010 y noviembre de 2021. Se reportaron los valores de CLL entre trasplantes y al año del TCPH. Las variables cuantitativas se describieron como mediana e intervalo intercuartil, y las variables categóricas como frecuencias absolutas y relativas. RESULTADOS: De 106 pacientes con amiloidosis AL, seis tuvieron TCO seguido de TCPH. La mediana de edad fue de 55 años. La mayoría eran hombres (n = 5). En el período entre trasplantes, la CLL involucrada disminuyó en dos pacientes y se mantuvo estable en tres. Todos lograron la remisión hematológica completa al año del TCPH. Un solo paciente presentó recaída en el órgano sólido trasplantado. Tacrolimus, micofenolato de mofetilo y corticoides fue el esquema inmunosupresor utilizado después del TCO. CONCLUSIONES: El TCO representa una opción de tratamiento en pacientes con falla cardíaca grave por amiloidosis, permitiendo luego un tratamiento intensivo con quimioterapia de inducción y TCPH. Si bien faltan estudios, la terapia inmunosupresora después del TCO podría tener algún efecto sobre las células plasmáticas clonales.

Assuntos

RESUMO

Despite recent advances in multiple myeloma (MM), the incorporation of novel agents and measurable residual disease (MRD) monitoring in low-income countries remains a challenge. Although lenalidomide maintenance (M-Len) after autologous stem cell transplantation (ASCT) has been associated with improved outcomes and MRD has refined the prognosis of complete response (CR) cases, until now, there have been no data on the benefits of these approaches in Latin America. Here, we evaluate the benefits of M-Len and MRD using next-generation flow cytometry (NGF-MRD) at Day + 100 post-ASCT (n = 53). After ASCT, responses were evaluated based on the International Myeloma Working Group criteria and NGF-MRD. MRD was positive in 60% of patients with a median progression-free survival (PFS) of 31 months vs. not reached (NR) for MRD-negative cases (p = 0.05). The patients who received M-Len continuously had a significantly better PFS and overall survival (OS) than those without M-Len (median PFS: NR vs. 29 months, p = 0.007), with progression in 11% vs. 54% of cases after a median follow-up of 34 months, respectively. In a multivariate analysis, MRD status and M-Len therapy emerged as independent predictors of PFS (median PFS of M-Len/MRD- vs. no M-Len/MRD+ of NR vs. 35 months, respectively; p = 0.01). In summary, M-Len was associated with improved survival outcomes in our real-world MM cohort in Brazil, with MRD emerging as a useful reproducible tool to identify patients at an earlier risk of relapse. The inequity in drug access remains a hurdle in countries with financial constraints, with a negative impact on MM survival.

RESUMO

Introducción: El mieloma múltiple es una neoplasia caracterizada por la proliferación de un clon de células plasmáticas monoclonales. Representa el 1 por ciento de todos los cánceres y el 10 por ciento de las neoplasias hematológicas. Las altas dosis de quimioterapia seguidas de trasplante autólogo de progenitores hematopoyéticos constituyen una opción terapéutica segura para un grupo seleccionado de pacientes. Objetivo: Analizar los resultados del trasplante autólogo de progenitores hematopoyéticos en pacientes con mieloma múltiple. Métodos: Estudio descriptivo, longitudinal, ambispectivo. El universo estuvo conformado por 14 pacientes (de los cuales se incluyeron 13) con diagnóstico de mieloma múltiple tratados con trasplante autólogo de progenitores hematopoyéticos de sangre periférica como tratamiento de consolidación, en el Instituto de Hematología e Inmunología de La Habana, desde enero de 2014 hasta diciembre de 2019. Resultados: La edad media fue de 53,9±5,6 años, predominó el sexo femenino. Las complicaciones más frecuentes fueron las infecciosas y la mucositis. La supervivencia global al año fue del 100 por ciento y del 80 por ciento a los cinco años. La supervivencia libre de progresión al año fue de 83 por ciento y 73 por ciento a los cinco años. Conclusiones: El trasplante hematopoyético autólogo de sangre periférica en pacientes con mieloma múltiple es un tratamiento que eleva las tasas de respuestas, la supervivencia global y libre de progresión y generalmente presenta pocas complicaciones(AU)

Introduction: Multiple myeloma is a neoplasm characterized by the presence of a plasmatic cells clone; accounts for 1 percent of cancers, and approximately 10 percent of hematologic malignancies. High dose chemotherapy followed by autologous stem cell transplantation remains a safe option in selected patients. Objective: To analyze the results of autologous stem cell transplantation from peripheral blood in patients with multiple myeloma. Methods: A descriptive, longitudinal, ambispective study. The universe was by 14 patients (13 of them were finally included), with diagnosis of multiple myeloma treated with autologous stem cell transplantation from peripheral blood at Institute of Hematology and Immunology of Havana from January 2014 to December 2019. Results: The median age of the patient was 53.9±5.6 years, with predominance of female sex. More frequents complications were infections and mucositis. A year overall survival was 100 percent and 80 percent at five years. Progression free survival at one and five years was 83 percent and 73 percent, respectively. Conclusions: The autologous stem cell transplantation in multiple myeloma patients increase complete responses, overall survival and progression free survival and is well accepted without severe complications(AU)

Assuntos

RESUMO

Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a multisystem autoinflammatory disease due to an underlying plasma cell disorder that lacks a standard treatment strategy because of its rarity. We report a case of relapsed POEMS syndrome successfully treated with a second ambulatory autologous hematopoietic-cell transplantation (AHCT) after a daratumumab desensitization protocol performed during the coronavirus disease (COVID-19) pandemic in a patient with coexisting human immunodeficiency virus (HIV), hepatitis B virus (HBV) and syphilis infections. He is a 37-year old Latin-American male who had been treated with radiation, CyBorD regimen, AHCT and bortezomib therapy before being referred to our service. It was decided to administer daratumumab therapy and subsequently perform the transplant. Placement of central venous access, fluid infusion, conditioning regimen with melphalan and previously cryopreserved autograft infusion were carried out in an outpatient basis. Following second AHCT, the patient demonstrated clinical, VEGF, hematological response and remains SARS-CoV-2 infection-free and in POEMS remission with excellent quality-of-life at last follow up (6 months). We evidenced that thanks to an outpatient transplant program, the best therapeutic modalities can be offered to patients with hematologic malignancies in the context of present or future pandemics. Finally, high-complexity patients with HIV infection should have access to the same treatment strategies as non-infected patients. A second AHCT in the outpatient setting is feasible, safe and highly effective to treat patients with relapsed POEMS syndrome.

Assuntos

RESUMO

Distal tibiofibular syndesmosis is a complex anatomical structure that is essential for the stability and function of the ankle. Ankle fractures are a common source of chronic syndesmosis instability with associated functional impairments and early development of osteoarthritis. Case presentation: we described a case of a 28-year-old patient who presented with symptomatic ankle subluxation and chronic syndesmosis instability. Eight months earlier, the patient sustained a minimally displaced ankle fracture that had been treated conservatively elsewhere. The surgical approach included the anatomical realignment of the distal fibula with a lengthening derotational osteotomy and tibiofibular syndesmosis reconstruction using an autologous semitendinosus tendon graft. One year after surgery, the ankle function was restored, and the patient was asymptomatic. Conclusion: The instability of ankle fractures should be carefully evaluated during the treatment decision-making. Surgical treatment of syndesmosis instability should be performed even in chronic cases to restore function. The reconstruction of syndesmosis with semitendinous tendon graft associated with fibular length and realignment improves the ankle stability and function.

RESUMO

Crohn's disease (CD) is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract. The etiology of CD is unknown; however, genetic, epigenetic, environmental, and lifestyle factors could play an essential role in the onset and establishment of the disease. CD results from immune dysregulation due to loss of the healthy symbiotic relationship between host and intestinal flora and or its antigens. It affects both sexes equally with a male to female ratio of 1.0, and its onset can occur at any age, but the diagnosis is most commonly observed in the range of 20 to 40 years of age. CD diminishes quality of life, interferes with social activities, traumatizes due to the stigma of incontinence, fistulae, strictures, and colostomies, and in severe cases, affects survival when compared to the general population. Symptoms fluctuate between periods of remission and activity in which complications such as fistulas, strictures, and the need for bowel resection, surgery, and colostomy implantation make up the most severe aspects of the disease. CD can be progressive and the complications recurrent despite treatment with anti-inflammatory drugs, corticosteroids, immunosuppressants, and biological agents. However, over time many patients become refractory without treatment alternatives, and in this scenario, hematopoietic stem cell transplantation (HSCT) has emerged as a potential treatment option. The rationale for the use of HSCT for CD is anchored in animal studies and human clinical trials where HSCT could reset a patient's immune system by eliminating disease-causing effector cells and upon immune recovery increase regulatory and suppressive immune cells. Autologous HSCT using a non-myeloablative regimen of cyclophosphamide and anti-thymocyte globulin without CD34+ selection has been to date the most common transplant conditioning regimen adopted. In this review we will address the current situation regarding CD treatment with HSCT and emphasize the medical, ethical, and legal aspects that permeate the procedure in Brazil.

RESUMO

INTRODUCTION: Insufficient hair growth after hair transplant, as well as erythema and perifollicular scaling, may be diagnosed as lichen planopilaris and treated as such based on clinical and histopathological findings. The purpose of this study is to observe graft biopsies of patients after uncomplicated hair transplants and to discuss if histological findings are enough to diagnose lichen planopilaris. METHODS AND RESULTS: Eight patients diagnosed with androgenetic alopecia who were submitted to hair transplant were enrolled. In each of the participants, a scalp biopsy was performed in the receptor area and in the adjacent area. Biopsies were performed between 6 months and 1 year after surgery. Exams were analyzed by 3 pathologists. The t test was performed for paired observations, comparing the transplanted and the nontransplanted area for lymphocytic infiltrate and fibrosis. The significance level was considered as 5% (p < 0.05). Four of 8 participants had perifollicular lymphocytic infiltrate, from moderate to dense intensity in the recipient area. Fibrosis was seen in 6 patients. These findings were not seen in the control area. CONCLUSIONS: It is questioned whether lymphocytic infiltrate and fibrosis may be expected in patients who are submitted to normal hair transplants.

RESUMO

RESUMEN Objetivo: Comparar los cambios dimensionales de los tejidos peri-implantarios en la zona estética, después de la segunda etapa quirúrgica de injertos de tejido conectivo autógeno comparados con una matriz de colágeno xenogénica, después de 3 meses de cicatrización. Métodos: En una serie de casos de seis pacientes con defectos del reborde alveolar, se realizó un procedimiento de aumento de volumen de tejidos blandos, asignando al azar dos modalidades de tratamiento: injerto de tejido conectivo subepitelial y matriz de colágeno dérmica acelular. Para evaluar los cambios dimensionales se tomaron impresiones antes del aumento y a los 90 días; estas fueron vaciadas para obtener modelos de yeso que fueron digitalizados; las dos imágenes fueron superpuestas; y tras la definición de tres puntos de interés, se calculó mediante un Software (D500 3D dental scanner - 3Shape, Copenhague, Dinamarca), los cambios dimensionales en milímetros. Se indagó por el dolor experimentado por los pacientes usando una escala visual análoga. Resultados: A los 90 días de realizada la cirugía, se observó un aumento en el grosor de los tejidos blandos peri-implantarios de 0,77 mm (rango 0,0-1,3) para el injerto de tejido conectivo, y 0,89 mm (rango 0,3-1,5) para la matriz dérmica acelular. No se encontraron diferencias estadísticamente significativas entre las dos modalidades de tratamiento, en ninguno de los tres puntos evaluados por paciente (p= 0,83; p= 0,83; p= 0,51). En cuanto al dolor experimentado entre el primer y séptimo días, no se encontraron diferencias estadísticamente significativas en la zona receptora intergrupo (p= 0,07; p= 0,12); intragrupo, injerto (p= 0,11) y matriz (p= 0,32); ni en la zona donante del grupo del injerto (p= 0,11). Conclusiones: El aumento en el grosor de los tejidos peri-implantarios fue similar después de 90 días en los dos grupos del estudio(AU)

ABSTRACT Objective: Compare the dimensional changes of peri-implant tissues from the esthetic zone after the second surgical stage of autogenous connective tissue grafting vs. a xenogenic collagen matrix after three months' healing. Methods: A case-series of six patients with alveolar ridge defects underwent a soft tissue volume augmentation procedure, randomly assigning two treatment modes: subepithelial connective tissue graft and acellular dermal collagen matrix. Impressions were taken before augmentation and at 90 days to evaluate the dimensional changes. These were then emptied to obtain plaster models which were then digitalized. The two images were superimposed, and upon definition of three points of interest, the dimensional changes were estimated in millimeters with the software D500 3D dental scanner (3Shape, Copenhagen, Denmark). Inquiries were made about the pain experienced by patients using a visual analogue scale. Results: Ninety days after surgery, increase in thickness of peri-implant soft tissues was 0.77 mm (range 0.0-1.3) for the connective tissue graft and 0.89 mm (range 0.3-1.5) for the acellular dermal matrix. No statistically significant differences were found between the two treatment modes at any of the three points evaluated per patient (p= 0.83, p= 0.83, p= 0.51). With respect to the pain experienced between the first and the seventh days, no statistically significant differences were found in the recipient zone intergroup (p= 0.07, p= 0.12), the graft intragroup (p= 0.11) and the matrix (p= 0.32), or in the donor zone of the graft group (p= 0.11). Conclusions: Increase in the thickness of peri-implant tissues after 90 days was similar in the two study groups(AU)

Assuntos

RESUMO

Over recent decades, there has been a considerable increase in use of endovascular methods to treat aortoiliac occlusive disease. It has been demonstrated that this approach offers many benefits, primarily for non-complex arterial lesions of the iliac axis, but difficulties persist with achieving adequate results over the medium and long term when treating extensive occlusive disease. Arterial bypasses to alternative vicarious arteries of the femoral-genicular complex for limb salvage are well known in the literature describing cases that are not favorable for conventional or endovascular surgery. We describe the case of a patient with extensive aortoiliac occlusive disease treated with an arterial bypass in the iliofemoral territory, using an alternative autologous substitute and the descending lateral femoral artery as recipient artery. Alternative bypasses and substitutes that are normally reserved for exceptional cases can and should be part of the vascular therapeutic arsenal and have a contribution to make in cases in which endovascular surgery does not yet enable us to achieve good results.

RESUMO

RESUMO Introdução: A resiliência apresenta-se como tema relevante de estudo no cotidiano do pós-transplante de células-tronco hematopoiéticas. Objetivo: identificar o nível de resiliência dos clientes no pós-transplante; e analisar os fatores de risco e de proteção, e expectativas presentes no cotidiano do pós-transplante. Metodos: Estudo qualitativo, realizado com 15 clientes no pós-transplante de células-tronco hematopoiéticas da Unidade de Transplante de Medula Óssea de um hospital universitário localizado no município do Rio de Janeiro, Brasil. Os dados foram coletados entre os meses de julho e agosto de 2011, por meio da Escala de Resiliência e da entrevista semiestruturada. Resultados: Os clientes apresentaram uma resiliência moderada, e da análise temática das entrevistas emergiram três subunidades: O tratamento que adoece e que faz perder a potência; Os suportes interno e externo: fortalecendo as estratégias de enfrentamento; e A superação como um processo. Conclusão: Os clientes se encontram em um processo de superação, uma vez que ainda vivenciam as dificuldades decorrentes do tratamento, requerendo estratégias adequadas de enfrentamento. Através dos pressupostos da resiliência, permitiu-se conhecer tais movimentos presentes neste universo, além de fomentar a necessidade de novas pesquisas dentro da temática(AU)

RESUMEN Introducción: La resiliencia presenta un tema relevante del estudio cotidiano post-trasplante de trasplante de células madre hematopoyéticas. Objetivo: Identificar el nivel de resiliencia de los clientes después del trasplante; y analizar el riesgo y los factores protectores presentes en el día a día post-trasplante. Métodos: estudio cualitativo realizado con 15 clientes en el post-trasplante de una unidad de trasplante de médula de un hospital universitario en la ciudad de Río de Janeiro, Brasil. Los datos fueron recolectados entre julio y agosto de 2011, por medio de la Escala de Resiliencia y entrevista semiestructurada. Resultados: Los clientes mostraron una resiliencia moderada, y el análisis temático de las entrevistas revelaron tres subunidades: tratamiento que hace enfermar y hace perder el poder; los soportes interno y externo: el fortalecimiento de las estrategias de supervivencia; y la superación como proceso. Conclusión: Los clientes estaban en un proceso de recuperación, ya que todavía experimentaban las dificultades resultantes del tratamiento, lo que requiere estrategias de afrontamiento adecuadas. A través de los supuestos de la capacidad de recuperación, se le permitió hacer frente a tales movimientos presentes en este universo, así como la promoción de la necesidad de nuevas investigaciones sobre el tema(AU)

ABSTRACT Introduction: Resilience is currently a topic worth studying in daily life for cases of hematopoietic stem cell transplantation. Objective: To identify the level of resilience of the clients after transplant and to analyze the risk and the protective factors present in the day-to-day post-transplant. Methods: Qualitative study conducted on 15 clients in the post-transplant of a bone marrow transplant unit of a university hospital in the city of Rio de Janeiro, Brazil. Data were collected between July and August 2011, through the Resilience Scale and a semi-structured interview. Results: Clients showed moderate resilience, and the thematic analysis of the interviews showed three subunits: treatment that makes people sick and lose power, internal and external supports (strengthening of survival strategies), and overcoming as a process. Conclusion: Clients were in a recovery process, as they still experienced the difficulties resulting from treatment, which requires adequate managing strategies. Through the assumptions of the capacity for recovery, they were allowed dealing with such movements present in this universe, as well as promoting the need for new research on the subject(AU)

Assuntos

RESUMO

The use of high-dose chemotherapy with autologous support of hematopoietic progenitor cells is an effective strategy to treat various hematologic neoplasms, such as non-Hodgkin lymphomas and multiple myeloma. Mobilized peripheral blood progenitor cells are the main source of support for autologous transplants, and collection of an adequate number of hematopoietic progenitor cells is a critical step in the autologous transplant procedure. Traditional strategies, based on the use of growth factors with or without chemotherapy, have limitations even when remobilizations are performed. Granulocyte colony-stimulating factor is the most widely used agent for progenitor cell mobilization. The association of plerixafor, a C-X-C Chemokine receptor type 4 (CXCR4) inhibitor, to granulocyte colony stimulating factor generates rapid mobilization of hematopoietic progenitor cells. A literature review was performed of randomized studies comparing different mobilization schemes in the treatment of multiple myeloma and lymphomas to analyze their limitations and effectiveness in hematopoietic progenitor cell mobilization for autologous transplant. This analysis showed that the addition of plerixafor to granulocyte colony stimulating factor is well tolerated and results in a greater proportion of patients with non-Hodgkin lymphomas or multiple myeloma reaching optimal CD34(+) cell collections with a smaller number of apheresis compared the use of granulocyte colony stimulating factor alone.

RESUMO

ABSTRACT The use of high-dose chemotherapy with autologous support of hematopoietic progenitor cells is an effective strategy to treat various hematologic neoplasms, such as non-Hodgkin lymphomas and multiple myeloma. Mobilized peripheral blood progenitor cells are the main source of support for autologous transplants, and collection of an adequate number of hematopoietic progenitor cells is a critical step in the autologous transplant procedure. Traditional strategies, based on the use of growth factors with or without chemotherapy, have limitations even when remobilizations are performed. Granulocyte colony-stimulating factor is the most widely used agent for progenitor cell mobilization. The association of plerixafor, a C-X-C Chemokine receptor type 4 (CXCR4) inhibitor, to granulocyte colony stimulating factor generates rapid mobilization of hematopoietic progenitor cells. A literature review was performed of randomized studies comparing different mobilization schemes in the treatment of multiple myeloma and lymphomas to analyze their limitations and effectiveness in hematopoietic progenitor cell mobilization for autologous transplant. This analysis showed that the addition of plerixafor to granulocyte colony stimulating factor is well tolerated and results in a greater proportion of patients with non-Hodgkin lymphomas or multiple myeloma reaching optimal CD34+ cell collections with a smaller number of apheresis compared the use of granulocyte colony stimulating factor alone.

Assuntos

RESUMO

Hematopoietic progenitor cells from peripheral blood (HPCPB) are commonly used for autologous and allogenic transplants in patients with most various onco-hematological diseases, and despite the utilization of sterile techniques during collection and processing of these products, bacterial contamination can occur. This study aimed to investigate the microbial contamination of HPCPB products. Microbial cultures of 837 HPCPB products between the year 2000 and 2009 were retrospectively analyzed to determine the incidence of culture positivity and identify the main organisms that cause contamination. The microbiological studies were performed with an automated system (BacT/Alert® bioMérieux Corporate). Thirty-six (4.3%) of 837 microbial cultures were contaminated. Coagulase-negative Staphylococcus was the most frequent bacteria isolated from HPCPB products (20 [56%] of the 36 positive microbial cultures). Considering the 36 contaminated samples, 22 HPCPB products were infused and 14 discarded. Pre-and post-infusion antibiotic therapy of the patients transfused with contaminated products was established based on the isolated microorganism and its antibiogram. Microbial contamination rate of HPCPB products was low. Clinically significant outcomes after infusion of contaminated HPCPB products were not observed.

Assuntos

RESUMO

Esta revisão da literatura descreve o processo do transplante autólogo de condrócitos em todas as suas etapas, indicações clínicas, técnica operatória, técnica laboratorial, reabilitação e resultados clínicos. Desde 1994, quando a técnica de ACI foi descrita pela primeira vez, este procedimento foi aprimorado e tornou-se uma das mais importantes alternativas cirúrgicas para o tratamento das lesões condrais do joelho. Nivel de Evidência II, Prospectivo Comparativo.

This literature review article describes the autologous chondrocyte implantation (ACI) process - its stages, clinical indications, surgical technique, laboratory protocol, rehabilitation and clinical outcomes. Since 1994, when the ACI was described for the first time, the procedure has improved to become one of the most important surgical alternatives for the treatment of chondral lesions of the knee.

Assuntos

RESUMO

In this review the authors present a state of art tretment of multiple myeloma.High dose chemo-radiotherapy followed by autologous hematopoietic stem cell transplantation has been show to be superior a conventional chemotherapy and a double transplantation. The authors discuss too, the allogeneic transplantation with reduced intensity conditioning, allogeneic versus tandem autologous, results the patients long term outcome and a approach about the use of donor lymphocytes, anti thimocyte globulin and a overview of post transplant therapies.

Neste relato os autores apresentam uma revisão sobre o estado atual do tratamento mieloma múltiplo. São enfatizados aspectos sobre a vantagem do transplante autólogo em seguimento à quimioterapia convencional e o duplo transplante. São discutidos o transplante alogênico e o condicionamento com intensidade reduzida, além do uso de linfócitos do doador, da globulina antitimocítica e uma visão geral do futuro da terapia da moléstia.

Assuntos

RESUMO

El trasplante de células hematopoyéticas (TCH) es la infusión de células progenitoras a fin de restablecer la función medular e inmune en pacientes con enfermedades hematológicas malignas y no malignas adquiridas y genéticas. El impacto del TCH se refleja en las alternativas de tratamiento, mayor difusión de la técnica y mejores opciones al paciente.El procedimiento consiste en la obtención de progenitores hematopoyéticos periféricos, mediante las células CD34+ (2- 2.5 x 106/Kg peso); es un excelente predictor de prendimiento del injerto. El trasplante de donante no relacionado, permite tratamiento a pacientes que carecen de donantes familiares histo-idénticos. Otra variante de TCH es el mini-trasplante, utilizando dosis bajas de quimioterapia e inmunosupresores, produciendo menos complicaciones, pero jerarquizando el efecto “injerto sobre tumor”, que permite la remisión de enfermedades neoplásicas hematológicas y no hematológicas, siendo una alternativa en países en vías de desarrollo, por la posibilidad de disminuir costos y complicaciones.

Transplant of Hematopoietic Stem Cells (HSCT) is the infusion of hematopoietic progenitor cells in patients with hematologic malignant, non malignant, acquired and genetic disorders of the bone marrow to reestablish inmune and marrow function. The impact of the HSCT reflects on the choices of treatment, the wide diffusion of the technique and better options to the patient.This procedure consist to obtain the peripheral hematopoietic progenitors; through the CD34+ cells (2–2.5 x 106/Kg) is an excellent predictor of the successful of the engraftment. Transplant from not-related donors allow treatment to patients who lack of haploidentical family donors. Other variable of HSCT is mini-transplant, using low-doses of chemotherapy and inmunosupressors, it produces less complications, and enhances the effect “graft vs tumor”. This allows the remission of the malignant hematologic and non-hematologic diseases. It is becoming a good choice for treatment in developing countries, because decrease costs and complications.

Assuntos